Tok Mustafa, Tüydeş Oktay, Yüksel Ahmet, Şenol Sefa, Akarsu Serkan
Department of Cardiovascular Surgery, Uludag University Faculty of Medicine, Bursa, Turkey.
Department of Cardiovascular Surgery, Bingol State Hospital, Bingol, Turkey.
Heart Surg Forum. 2016 Jun 20;19(3):E118-22. doi: 10.1532/hsf.1496.
The purpose of this study was to present early-term outcomes of VariClose® Vein Sealing System, which is a novel, non-thermal, and non-tumescent percutaneous embolization technique for treatment of saphenous vein insufficiency.
Between March 2014 and July 2015, 189 saphenous veins in 141 patients were treated with Variclose Vein Sealing System containing n-butyl cyanoacrylate. Pre-, intra-, post-procedural, and follow-up data of patients were collected and retrospectively reviewed.
Mean age of patients was 42.5 ± 14.0 years, of which 53% were female. Technical success rate of intervention was 98.9%. Mean procedure time was 14.3 ± 7.5 minutes. Eighty-nine percent of patients (n = 126/141) were available at mean follow-up time of 6.7 months. Mean Venous Clinical Severity Score was significantly improved from 8.3 ± 2.2 at pre-procedure period to 3.3 ± 1.8 at follow-up. No complete recanalization was observed, but 2 patients were presented with partial recanalization during follow-up. The complete occlusion rate was 98.4%. No serious adverse event related to procedure was observed.
Variclose Vein Sealing System appears to be safe and effective in treatment of saphenous vein insufficiency. Further randomized studies with long-term outcomes are required for determining optimal treatment modality in patients with saphenous vein insufficiency.
本研究旨在介绍VariClose®静脉封闭系统的早期治疗效果，该系统是一种用于治疗大隐静脉功能不全的新型、非热、非肿胀性经皮栓塞技术。
2014年3月至2015年7月期间，对141例患者的189条大隐静脉采用含氰基丙烯酸正丁酯的Variclose静脉封闭系统进行治疗。收集患者术前、术中、术后及随访数据，并进行回顾性分析。
患者平均年龄为42.5±14.0岁，其中53%为女性。介入治疗的技术成功率为98.9%。平均手术时间为14.3±7.5分钟。89%的患者（n = 126/141）在平均随访时间6.7个月时可获得随访。静脉临床严重程度评分从术前的8.3±2.2显著改善至随访时的3.3±1.8。随访期间未观察到完全再通，但有2例患者出现部分再通。完全闭塞率为98.4%。未观察到与手术相关的严重不良事件。
Variclose静脉封闭系统在治疗大隐静脉功能不全方面似乎是安全有效的。需要进一步进行长期结果的随机研究，以确定大隐静脉功能不全患者的最佳治疗方式。
